Given that IL-6is the key growth and survival factor of multiple myeloma cells, and isparticularly involved in the origin of all benign and malignant plasma cellexpansions as well as MM cell resistance, the effects and targets of the PPARγ ligands on aspects of multiple myelomabiology and bone marrow stromal cells may be clinically relevant. This evidence concerns the gene PPARG and Miyoshi myopathy.